AstraZeneca announced a co-commercialisation agreement with Daiichi Sankyo for MOVANTIK (naloxegol) Read the full story

Daiichi Sankyo and Ambit Biosciences announced the company acquisition of the Ambit in a deal valued up to $410 million. Read the full story

Charleston Laboratories and Daiichi Sankyo announced that the parties have entered into a strategic collaboration for the development and U.S. commercialization of Charleston Laboratories' novel hydrocodone combination products. Read the full story

The term 'top pharma' can relate to the top pharmaceutical companies or the top 10 or 50... Read the full story

Sun Pharmaceutical agreed to m&a transaction to buy competitor Ranbaxy Laboratories for $3.2 billion from Japan’s Daiichi Sankyo, which paid 61 percent more for the company five years ago. Read the full story

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan Read the full story

Big pharmas Astellas Pharma and Daiichi Sankyo announced the companies would form a compound library sharing partnership for approximately 400,000 selected compounds. Read the full story

Daiichi Sankyo is a global pharmaceutical company engaged in the research and development, manufacturing, and sale and marketing of innovative and generic drugs, vaccines, and over-the counter medicines Read the full story

Daiichi Sankyo has announced over 45 partnering / licensing deals since 2005, with 5 deals in 2012 alone Read the full story

Daiichi Sankyo has announced only 6 M&A deals since 2005 Read the full story